Literature DB >> 26254725

Differentiating between benign and malignant adnexal lesions with contrast-enhanced transvaginal ultrasonography.

Marek Szymanski1, Maciej W Socha1, Magdalena E Kowalkowska2, Izabela B Zielińska3, Andrzej Eljaszewicz4, Wieslaw Szymanski1.   

Abstract

OBJECTIVE: To analyze the relationship between contrast kinetics in tumorous vessels and lesion histologic type in an attempt to differentiate between malignant and benign disease.
METHODS: In a single-center prospective study, patients who had been referred for elective surgery because of a diagnosis of unilateral and/or bilateral adnexal masses were enrolled at Dr Jan Biziel University Hospital, Bydgoszcz, Poland, between January 2012 and September 2013. Participants underwent contrast-enhanced ultrasonography examination (CEUS). Contrast kinetics were obtained and compared with the neovascularization of the tumor. Accuracy, and positive and negative predictive values were calculated.
RESULTS: Among 160 enrolled patients, 84 underwent CEUS examination and 51 lesions were studied. Baseline and maximum color Doppler intensities were significantly higher in malignant than in benign tumors (P < 0.001 for both). Similarly, the absolute and relative increases in color Doppler intensity were significantly higher in malignant tumors (P < 0.001). The estimated positive predictive value was 97.1%, the negative predictive value was 100%, and the accuracy was 100%. Peak enhanced intensity of fractional color Doppler Area and area under the time-intensity curve (S-parameter) correlated significantly with the histology of the lesion (P < 0.001). Probability curves demonstrated that higher S-parameter values were correlated with a higher risk of malignancy.
CONCLUSION: Transvaginal CEUS is a reliable and reproducible way to differentiate between benign and malignant adnexal lesions.
Copyright © 2015 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adnexal lesion; Contrast-enhanced ultrasonography; Differential diagnosis; Ovarian cancer; Pelvic mass

Mesh:

Substances:

Year:  2015        PMID: 26254725     DOI: 10.1016/j.ijgo.2015.04.047

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  7 in total

1.  Characterization of Adnexal Masses Using Contrast-Enhanced Subharmonic Imaging: A Pilot Study.

Authors:  Lauren J Delaney; Priscilla Machado; Mehnoosh Torkzaban; Andrej Lyshchik; Corinne E Wessner; Christine Kim; Norman Rosenblum; Scott Richard; Kirk Wallace; Flemming Forsberg
Journal:  J Ultrasound Med       Date:  2019-11-26       Impact factor: 2.153

2.  Screening for ovarian cancer: imaging challenges and opportunities for improvement.

Authors:  K B Mathieu; D G Bedi; S L Thrower; A Qayyum; R C Bast
Journal:  Ultrasound Obstet Gynecol       Date:  2018-03       Impact factor: 7.299

3.  Clinical value of combining transvaginal contrast-enhanced ultrasonography with serum human epididymisprotein-4 and the resistance index for early-stage epithelial ovarian cancer.

Authors:  Wu Meng; Wang Ying; Zheng Qichao; Li Ping; Tang Jie
Journal:  Saudi Med J       Date:  2017-06       Impact factor: 1.484

Review 4.  Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.

Authors:  Juliane M Liberto; Sheng-Yin Chen; Ie-Ming Shih; Tza-Huei Wang; Tian-Li Wang; Thomas R Pisanic
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

Review 5.  Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives.

Authors:  Giovanni Di Lorenzo; Giuseppe Ricci; Giovanni Maria Severini; Federico Romano; Stefania Biffi
Journal:  Theranostics       Date:  2018-07-30       Impact factor: 11.556

6.  Targeted Fe-doped silica nanoparticles as a novel ultrasound-magnetic resonance dual-mode imaging contrast agent for HER2-positive breast cancer.

Authors:  Xiaoyu Li; Shujun Xia; Wei Zhou; Ri Ji; Weiwei Zhan
Journal:  Int J Nanomedicine       Date:  2019-04-05

7.  Biomarkers and Strategies for Early Detection of Ovarian Cancer.

Authors:  Robert C Bast; Zhen Lu; Chae Young Han; Karen H Lu; Karen S Anderson; Charles W Drescher; Steven J Skates
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-13       Impact factor: 4.254

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.